MENU
+Compare
XBIO
Stock ticker: NASDAQ
AS OF
Jul 25 closing price
Price
$3.60
Change
-$0.04 (-1.10%)
Capitalization
5.56M

XBIO Xenetic Biosciences Forecast, Technical & Fundamental Analysis

Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing innovative immuno-oncology technologies addressing difficult to treat cancers... Show more

Industry: #Biotechnology
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for XBIO with price predictions
Jul 25, 2025

XBIO's Stochastic Oscillator is staying in oversold zone for 7 days

The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

XBIO moved above its 50-day moving average on June 24, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where XBIO advanced for three days, in of 239 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for XBIO moved out of overbought territory on June 27, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on July 15, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on XBIO as a result. In of 94 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XBIO turned negative on July 15, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where XBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

XBIO broke above its upper Bollinger Band on June 25, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.085) is normal, around the industry mean (18.028). P/E Ratio (0.000) is within average values for comparable stocks, (59.593). XBIO's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.512). Dividend Yield (0.000) settles around the average of (0.044) among similar stocks. P/S Ratio (2.151) is also within normal values, averaging (278.844).

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. XBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
XBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

XBIO is expected to report earnings to fall 81.36% to -10 cents per share on May 17

Xenetic Biosciences XBIO Stock Earnings Reports
Q1'23
Est.
$-0.11
Q1'25
Beat
by $0.13
Q4'24
Missed
by $0.51
Q4'22
Est.
$-0.10
Q3'22
Est.
$-0.06
The last earnings report on May 13 showed earnings per share of -58 cents, beating the estimate of -72 cents. With 88.58K shares outstanding, the current market capitalization sits at 5.56M.
A.I. Advisor
published General Information

General Information

a developer of biologic drugs, novel oncology therapeutics, and vaccinations

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
945 Concord Street
Phone
+1 781 778-7720
Employees
4
Web
https://www.xeneticbio.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
SONO11.25-0.03
-0.27%
Sonos
KE18.67-0.11
-0.59%
Kimball Electronics
XNET4.95-0.04
-0.80%
Xunlei Limited
INM2.64-0.04
-1.49%
InMed Pharmaceuticals Inc
DOC17.60-1.27
-6.73%
Healthpeak Properties

XBIO and Stocks

Correlation & Price change

A.I.dvisor tells us that XBIO and NKTR have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that XBIO and NKTR's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XBIO
1D Price
Change %
XBIO100%
-1.00%
NKTR - XBIO
27%
Poorly correlated
+1.71%
ELEV - XBIO
27%
Poorly correlated
N/A
VERA - XBIO
27%
Poorly correlated
-0.32%
ALT - XBIO
26%
Poorly correlated
N/A
CGEN - XBIO
24%
Poorly correlated
-0.65%
More